Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.
In patients with sarcoidosis, cancer was found to develop earlier in men vs women.
When evaluating a patient with newly identified interstitial lung disease, using a questionnaire may help clinicians identify potentially relevant exposures for hypersensitivity pneumonitis.
The use of exhaled breath analysis via eNose technology can help accurately distinguish various subtypes of interstitial lung disease.
In patients with idiopathic pulmonary fibrosis, treatment with pirfenidone was associated with a lower risk of mortality and acute respiratory-related hospitalizations than treatment with nintedanib.
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.
Researchers confirmed the feasibility of conducting a randomized, triple-blinded, sham-controlled trial of ambulatory oxygen delivered via portable oxygen concentrator to evaluate its effects in patients with interstitial lung disease.
A new genomic classifier added to bronchoscopic lung cryobiopsy increased the diagnostic confidence of physicians for interstitial lung disease.